The role of endothelin in the pathogenesis of heart failure

Current Cardiology Reports

Volumn 4, Issue 3, 2002, Pages 206-212

  Teerlink, John R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ANIMAL; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; VASOCONSTRICTION;

ANIMALS; CLINICAL TRIALS; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, ANIMAL; RECEPTORS, ENDOTHELIN; VASOCONSTRICTION;

EID: 0036584133     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0052-2     Document Type: Article

References (50)

1. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985, 248:C550-C556.
2. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
3. Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391-415.
4. Xu D, Emoto N, Giaid A, et al.: ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994, 78:473-485.
5. Serneri GG, Cecioni I, Vanni S, et al.: Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res 2000, 86:377-385.
6. Teerlink JR, Carteaux JP, Sprecher U, et al.: Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol Heart Circ Physiol 1995, 268:H432-H440.
7. Cernacek P, Stewart DJ: Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989, 161:562-567.
8. Margulies KB, Hildebrand FL, Jr., Lerman A, et al.: Increased endothelin in experimental heart failure. Circulation 1990, 82:2226-2230.
9. JR, Löffler BM, Hess P, et al.: Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994, 90:2510-2518. This study demonstrated that endothelin receptor antagonists have important hemodynamic effects even in the context of ACE inhibitors.
10. Cody RJ, Haas GJ, Binkley PF, et al.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85:504-509.
11. McMurray JJ, Ray SG, Abdullah I, et al.: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
12. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC, Jr.: Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992, 20:849-853.
13. Wei CM, Lerman A, Rodeheffer RJ, et al.: Endothelin in human congestive heart failure. Circulation 1994, 89:1580-1586.
14. Pacher R, Stanek B, Hülsmann M, et al.: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641. In this study, endothelin levels, as represented by the precursor big ET, are demonstrated to be powerful predictors of mortality in heart failure patients.
15. Kobayashi T, Miyauchi T, Sakai S, et al.: Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol Heart Circ Physiol 1999, 276:H1197-H1206.
16. Thorin E, Lucas M, Cernacek P, Dupuis J: Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure. Am J Physiol Heart Circ Physiol 2000, 279:H844-H851.
17. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852-854.
18. Gray GA, Löffler BM, Clozel M: Characterization of endothelin receptors mediating contraction of rabbit saphenous vein. Am J Physiol 1994, 266:H959-H966.
19. Teerlink JR, Breu V, Sprecher U, et al.: Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 1994, 74:105-114.
20. Love MP, Haynes WG, Gray GA, et al.: Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996, 94:2131-2137.
21. Kanse SM, Wijelath E, Kanthou C, et al.: The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest 1995, 72:376-382.
22. Davie N, Haleen SJ, Upton PD, et al.: ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002, 165:398-405.
23. Loennechen JP, Støylen A, Beisvag V, et al.: Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2001, 280:H2902-H2910.
24. Tsutamoto T, Wada A, Maeda K, et al.: Transcardiac extraction of circulating endothelin-1 across the failing heart. Am J Cardiol 2000, 86:524-528.
25. Piacentini L, Gray M, Honbo NY, et al.: Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol 2000, 32:565-576.
26. Belloni AS, Rossi GP, Andreis PG, et al.: Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996, 27:1153-1159.
27. Yoshida K, Yasujima M, Kohzuki M, et al.: Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992, 20:292-297.
28. Kaddoura S, Firth JD, Boheler KR, et al.: Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 1996, 93:2068-2079.
29. Riggleman A, Harvey J, Baylis C: Endothelin mediates some of the renal actions of acutely administered angiotensin II. Hypertension 2001, 38:105-109.
30. Ramires FJA, Sun Y, Mady C, et al.: Effect of endothelin on myocardial fibrosis in response to chronic administration of angiotensin II or aldosterone [abstract]. Circulation 1999, 100:I-474.
31. Duru F, Barton M, Lüscher TF, Candinas R: Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res 2001, 49:272-280.
32. Yorikane R, Shiga H, Miyake S, Koike H: Evidence for direct arrhythmogenic action of endothelin. Biochem Biophys Res Commun 1990, 173:457-462.
33. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ: Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 2000, 292:449-459.
34. Grover GJ, Dzwonczyk S, Parham CS: The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993, 27:1613-1618.
35. Burke SE, Nelson RA: Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion. J Cardiovasc Pharmacol 1997, 29:87-92.
36. Sakai S, Miyauchi T, Kobayashi M, et al.: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355. This study was the first to demonstrate that the administration of an endothelin receptor antagonist (BQ-123, an ETA-selective antagonist) could improve survival in the rat coronary artery ligation model of heart failure.
37. Mulder P, Richard V, Bouchart F, et al.: Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998, 39:600-608.
38. Nguyen QT, Cernacek P, Calderoni A, et al.: Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998, 98:2323-2330.
39. Hu K, Gaudron P, Schmidt TJ, et al.: Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction. J Cardiovasc Pharmacol 1998, 32:505-508.
40. Podesser BK, Siwik DA, Eberli FR, et al.: ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol 2001, 280:H984-H991.
41. Spinale FG, Walker JD, Mukherjee R, et al.: Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 1997, 95:1918-1929.
42. Moe GW, Albernaz A, Naik GO, et al.: Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res 1998, 39:571-579.
43. Clozel M, Breu V, Gray GA, et al.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994, 270:228-235.
44. Mulder P, Richard V, Derumeaux G, et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997, 96:1976-1982. This study demonstrated the ability of the orally available dual (ETA/ ETB) receptor antagonist to attenuate adverse ventricular remodeling and improve survival in rats with chronic heart failure.
45. Fraccarollo D, Hu K, Galuppo P, et al.: Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997, 96:3963-3973.
46. Oie E, Bjonerheim R, Grogaard HK, et al.: ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats. Am J Physiol 1998, 275:H868-H877.
47. Iwanaga Y, Kihara Y, Inagaki K, et al.: Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 2001, 104:606-612.
48. Mishima T, Tanimura M, Suzuki G, et al.: Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000, 35:222-229.
49. Mylona P, Cleland JG: Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1999, 1:197-200. This brief summary of the REACH-1 trial, a study of the effects of the endothelin receptor antagonist, bosentan, on patients with CHF, suggested that there was a beneficial clinical effect in patients treated for 6 months. Although the study was stopped early due to recognition of problems with dosing and related increases in liver transaminases, these results were very encouraging, and provided the basis for the ENABLE trial.
50. Thackray SD, Witte KK, Khand A, et al.: Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. Eur J Heart Fail 2001, 3:117-124.